NSI 189

Drug Profile

NSI 189

Alternative Names: NSI-189; NSI-189 phosphate

Latest Information Update: 03 Mar 2017

Price : $50

At a glance

  • Originator Neuralstem
  • Class Antidepressants; Piperazines; Pyridines; Small molecules
  • Mechanism of Action Neurogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Major depressive disorder
  • Preclinical Alzheimer's disease; Angelman syndrome; Brain injuries; Cognition disorders; Neurodegenerative disorders; Post-traumatic stress disorders; Stroke

Most Recent Events

  • 28 Feb 2017 Pharmacodynamics data from a preclinical trial in Stroke released by Neuralstem
  • 22 Feb 2017 Neuralstem has patent protection for NSI 189 in USA
  • 16 Feb 2017 Neuralstem completes enrolment in its phase II trial for Major depressive disorder in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top